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ABSTRACT  
 
BACKGROUND AND AIMS: Sub-clinical inflammatory changes are commonly 
described in long-term transplant recipients undergoing protocol liver biopsies. 
The pathogenesis of these lesions remains unclear. The aim of the study was to 
identify the key molecular pathways driving progressive sub-clinical 
inflammatory liver allograft damage. 
PATIENTS AND METHODS: All liver recipients followed at Hospital Clínic 
Barcelona who were >10 years post-transplant were screened to participate in 
the study. Patients with recurrence of underlying liver disease, biliary or 
vascular complications, chronic rejection, and abnormal liver function tests were 
excluded. Sixty-seven patients agreed to participate and underwent blood and 
serological tests, transient elastography and a liver biopsy. Transcriptome 
profiling was performed on RNA extracted from 49 out of the 67 biopsies 
employing a whole genome next generation sequencing platform. Patients were 
followed for a median of 6.8 years following the index liver biopsy. 
RESULTS: Median time since transplantation to liver biopsy was 13 years (10-
22). The most frequently observed histological abnormality was portal 
inflammation with different degrees of fibrosis, present in 45 biopsies (67%). 
Two modules of 102 and 425 co-expressed genes were significantly correlated 
with portal inflammation, interface hepatitis and portal fibrosis. These modules 
were enriched in molecular pathways known to be associated with T cell 
mediated rejection. Liver allografts showing the highest expression levels for the 
two modules recapitulated the transcriptional profile of biopsies with clinically 
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apparent rejection and developed progressive damage over time, as assessed 
by non-invasive markers of fibrosis.  
CONCLUSIONS: A large proportion of long-term surviving adult liver transplant 
recipients exhibit subclinical histological abnormalities whose expression profile 
closely resembles T cell mediated rejection and that may result in progressive 
allograft damage.  
 
 
Lay summary: A large proportion of long-term surviving adult liver transplant 
recipients exhibit subclinical histological abnormalities. Transcriptome profiling 
of liver tissue showed an expression profile that closely resembles T cell 
mediated rejection.  Liver allografts showing the highest expression levels of 
rejection-related genes developed progressive damage over time.  
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INTRODUCTION 
 
Routine serum markers of liver injury such as aspartate and alanine 
aminotransferases (AST, ALT), gamma-glutamyl-transpeptidase (GGT) or 
alkaline phosphatase (AP) are known to be insensitive and nonspecific 
indicators of allograft rejection in liver transplantation (LT) [1,2]. Despite this, the 
long-term management of LT recipients continues to rely on a combination of 
serum liver biochemistry tests and calcineurin inhibitor pharmacokinetic 
markers. The performance of protocol, or surveillance, liver biopsies has been 
proposed as a more accurate strategy to assess graft function and potentially to 
personalize the use of immunosuppression [3–5]. This is based on a multiplicity 
of studies showing that a very large proportion of patients with normal liver 
biochemistry tests exhibit clinically significant histological lesions, with chronic 
hepatitis not attributable to recognizable causes such as viral infection or 
autoimmune hepatitis being the most frequently described abnormality [1,6–8]. 
The clinical utility of protocol liver biopsies, however, remains contentious [5], 
and as a result they are not performed in the vast majority of adult liver 
transplant programs. The controversy stems from an incomplete understanding 
of the natural history and pathogenesis of the so-called idiopathic inflammatory 
lesions [2,9]. This is due to the paucity of prospective clinical studies and the 
lack of in-depth studies comparing the molecular signatures of these lesions 
with those of well-characterized histological phenotypes.   
Employing microarray and real-time PCR analyses, we previously reported that 
it is possible to identify transcriptional signatures of acute cellular rejection in 
blood and liver tissue specimens of LT recipients [10,11]. Importantly, these 
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signatures can be detected even in the midst of the noise caused by other 
forms of chronic inflammation, such as that induced by hepatitis C virus (HCV). 
We anticipated that a similar strategy could provide a clue as to the 
pathogenesis of idiopathic fibro-inflammatory lesions in long-term surviving 
adult liver transplant recipients. To confirm this premise, we conducted a 
prospective clinical study in which we approached all surviving LT recipients 
transplanted at Hospital Clinic Barcelona between 1988 and 1999 without 
previously diagnosed allograft lesions, and performed liver biopsy, transient 
elastrography, and next generation sequencing transcriptional studies.  
 
PATIENTS AND METHODS  
 
Patient population 
Between December 2007 and December 2009 we screened all patients who 
had undergone LT at Hospital Clínic Barcelona between 1988 and 1999 and 
who remained alive and had been followed-up for more than 10 years after 
transplantation. Exclusion criteria were: 1) diagnosis of de novo or recurrent 
liver disease after transplantation, including HCV-related hepatitis; 2) elevation 
in AST, ALT or AP ≥2 fold above the upper limit of normality (isolated GGT 
increases were not considered an exclusion criteria [n=18]); 3) T cell-mediated 
rejection within 1 year of the inclusion in the study; 4) contraindications for a 
liver biopsy; 5) severe extra-hepatic co-morbidities (Figure 1).  All consented 
patients underwent a protocol liver biopsy and collection of a blood specimen.  
Patients included in the study were followed-up until death, re-transplantation, 
lost to follow-up or December 2017.  
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All patients signed an informed consent. The study was approved by the 
ethical committee at Hospital Clínic Barcelona. 
 
Laboratory tests and fibrosis evaluation 
The following tests were performed at the time of inclusion: liver tests (serum 
AST, ALT, GGT, AP, total bilirubin, INR); platelet count; serologies for hepatitis 
B (surface antigen HBsAg, anti-core antibodies), hepatitis C, and hepatitis E 
(IgG anti-hepatitis E antibodies and RNA) viruses; and serum autoantibodies 
(anti-nuclear antibodies ANA, anti-smooth muscle antigen SMA, anti-liver-
kidney microsomal antibodies anti-LKM1/2). Liver tests and platelet counts were 
also analyzed at the last follow-up visit.  Indirect fibrosis scores (APRI and FIB-
4) were calculated using the standard formulas at the time of inclusion and at 
the last follow-up [12,13].  In addition, 30 patients underwent a liver stiffness 
measurement (LSM) with Fibroscan® transient elastography (Echosens, 
France) at the time of liver biopsy.  
 
Liver histopathology  
Hematoxylin-eosin and Masson’s trichrome stained sections were blindly 
assessed by two liver histopathologists (RM and LNS). A semi-quantitative 
score was used to evaluate and grade different parameters as follows: 1) 
Architectural abnormalities: 0= absent; 1= minimal abnormalities consistent with 
irregular regenerative foci; and 2= moderate-marked with parenchymal atrophy 
and centrilobular collapse (with or without inflammation) or nodular regenerative 
hyperplasia;  2) Lobular inflammation: 0= no inflammation; 1= mild (sinusoidal 
inflammatory cells and/or mild focal necrosis); 2= moderate (multiple necro-
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inflammatory foci); and 3= marked (confluent or bridging necrosis);  3) Central 
perivenulitis (with or without endotheliitis): 0= no inflammation; 1= mild (patchy, 
focal perivenulitis); 2= moderate (perivenulitis in most central veins); and 3= 
marked (confluent or bridging hepatocellular necrosis); 4) Portal inflammation: 
0= no inflammation; 1= mild (small groups of inflammatory cells); 2=moderate 
(expansive inflammatory infiltrate in >50% of portal tracts); and 3=marked 
(severe inflammatory infiltrate in most portal tracts), 5) Interface hepatitis: 0= no 
interface activity; 1= mild; 2= moderate; and 3=severe; 6) Bile duct lesion: 0= 
no; 1= minimal (intraepithelial inflammatory cells or abnormal colangiocytes); 2= 
moderate (epithelial lesions in most portal tracts, no destruction); and 3= 
marked (destructive epithelial lesions in most portal tracts); 7)  Bile duct loss: 0= 
no loss; 1= loss of bile ducts in <50% of the portal tracts; and 2= loss in ≥ 50% 
of the portal tracts; 8) Portal vein branches: 0= present in all portal tracts; 1= 
absent in a minority of portal tracts; and 2=absent in most portal tracts; 9) Portal 
vein endotheliitis: 0=absent; 1= mild (present in a minority of portal veins); 
2=moderate (present in most portal veins); and 3= marked; 10) Portal fibrosis: 
0= absent; 1=minimal fibrosis (minority of portal tracts); 2= moderate (periportal 
expansion in most portal tracts); 3= bridging fibrosis; 4= cirrhosis; 11) Peri-
sinusoidal fibrosis: 0=absent; 1= focal; 2=marked; 12) Steatosis: 0= mild (< 30% 
of hepatocytes); 1= moderate (30-60%); and 2= severe (> 60% of hepatocytes).  
 
Statistical analysis 
Categorical data were compared by Chi-squared or Fischer’s test as 
appropriate. Continuous variables were compared by non-parametric testing 
(Mann-Whitney).  A cumulative odds ordinal logistic regression with 
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proportional odds was run to determine the effect of severity of portal 
inflammation on the risk of having portal fibrosis. We employed non-
parametric analysis of covariance (ANCOVA) adjusting for a smooth nonlinear 
effect of baseline using a spline function to rigorously explore the effects of 
module gene expression assignment on the following continuous variables: 
bilirubin, AST, ALT, INR, platelet count, APRI and FIB4. Data are reported as 
adjusted mean difference and 95% confidence interval (95%CI).  Statistical 
analyses were performed using SPSS statistical package version 23 and R. 
 
RNA extraction 
RNA was extracted from formalin-fixed, paraffin-embedded liver biopsy 
specimens. First, excessive paraffin surrounding the tissue was manually 
removed from the blocks and 8 sections of 5um each were obtained and placed 
in Eppendorf tubes. Tissue RNA was then isolated following deparaffinization, 
incubation with lysis buffer and DNase treatment according to the RNeasy® 
FFPE kit’s instructions (Qiagen, UK).  RNA was eluted using a RNeasy 
MinElute® spin column following ethanol addition. The concentration and purity 
of the RNA was measured using Nanodrop (ThermoScientific) and Qubit RNA 
BR Assay kit (Bio-Rad, Hercules, CA), and the RNA stored at -80oC. 
 
RNA Sequencing (RNASeq) experiments 
Out of the 67 protocol liver biopsies performed as part of the study, 49 were 
employed to conduct RNASeq experiments, while in the remaining cases this 
could not be completed due to insufficient liver tissue material, poor quality RNA 
or sub-optimal sequenced reads. RNASeq was done in collaboration with 
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Genetracer Biotech using the Ion Torrent Proton II (Thermo Fisher), which 
employs custom designed primers targeting multiple exons for all known protein 
coding genes as primary transcript detection strategy. Briefly, 50ng RNA was 
used to generate sequencing libraries using the Ion AmpliSeq™ Transcriptome 
Human Gene Expression Kit (Thermo Fisher), and barcoded using Ion Express 
barcodes. cDNA library quality was assessed using the Agilent® 2200 
TapeStation System and the High Sensitivity D1000 ScreenTape System 
(Agilent Technologies, Santa Clara, CA). Templates were run on the Ion PI™ v3 
chips using the Ion Chef system and Hi-Q™ Chef kits. Sequencing depth per 
sample was 12 million genome-aligned reads. Sequenced reads were mapped 
against the reference sequences including 20,800 different genes present in the 
AmpliSeq Human Gene Expression panel using Novalign software V3.02.08 
(http://www.novocraft.com).  Novoalign finds global optimum alignments using 
full Needleman–Wunsch algorithm showing better sensitivity than other aligners 
[14]. After mapping, unique mapped reads were summarized as counts 
representing the gene expression levels for over 20,800 different genes present 
in the AmpliSeq Human Gene Expression panel. Low expressed genes were 
excluded from downstream analysis if the sum of counts were lower than 100. 
Transformation of count data to log2-counts per million (logCPM) was 
accomplished estimating the mean-variance relationship and using this 
parameter to compute appropriate observational-level weights. The resulting 
data was then used for linear modeling and differential expression by means of 
the Limma R-package [15]. Fold-changes, moderated P values, and false 
discovery rates (FDR) obtained by adjusting P values for multiple testing using 
Benjamini-Hochberg, were calculated. Additional RNASeq experiments were 
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performed on RNA samples extracted from 18 archived diagnostic liver biopsies 
conducted at Hospital Clinic Barcelona during 2009. These for-cause biopsies 
were performed in patients with allograft dysfunction and corresponded to 8 
samples of early T cell mediated rejection (within 3 months post-transplant); 6 
samples of late (>1 year post-transplant) T cell mediated rejection; and 4 
samples of post-transplant recurrent HCV infection. Transcriptional data derived 
from the 18 for-cause biopsies were employed exclusively for functional 
pathway analysis and were not included in the remaining analyses.   
The raw data from Ion-Torrent ampliseq transcriptome were deposited in the 
National Center for Biotechnology Information (NCBI; Bethesda, MD, USA) 
Short Read Archive data-base (Bioproject accession no. PRJNA437250; 
https://www.ncbi.nlm.nih.gov/sra). 
 
Analysis of gene expression data 
To explore the correlation patterns among genes across the RNASeq data 
derived from the 49 protocol biopsies we employed the Weighted Gene 
Correlation Network Analysis (WGCNA) software package available from R 
[16]. To perform WGCNA, correlations between all pairs of genes in the 
expression dataset were quantified and transformed into measures of 
connection strength by emphasizing strong correlations and minimizing the 
noise in the pairwise measurements. A hierarchical clustering algorithm was 
then used to identify modules of highly interconnected genes. Next, to reduce 
multi-dimensionality, consensus eigengenes were defined for each module and 
used to relate the modules to external data (e.g. clinical traits).  
The statistical significance of a priori defined sets of genes representing 
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biological pathways on the whole transcriptional dataset, which included the 49 
protocol biopsies plus the 18 for-cause biopsies, was computed employing 
Quantitative Set Analysis for Gene Expression (QuSAGE) [17], using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway database and the 
transplantation-related Pathogenesis-Based Transcript (PBT) gene sets from 
the Alberta Transplant Applied Genomics Centre (ATAGC; 
http://atagc.med.ualberta.ca/Research/GeneLists). For QuSAGE analysis the 
threshold of statistical significance was set at FDR<0.10. To identify pathways 
enriched in modules of co-expressed genes we employed the enricher function 
from ClusterProfiler R-package for hypergeometric tests. 
To interrogate whether biopsies exhibiting idiopathic inflammatory lesions were 
likely to correspond to unrecognized forms of rejection, we re-analyzed a liver 
tissue microarray dataset derived from two immunosuppression withdrawal 
trials previously reported by our group, which contained expression data from 
20 pairs of liver biopsies obtained before drug weaning was initiated and at the 
time of rejection [11].  A gene classifier of T cell mediated rejection was 
identified using Predictive Analysis of Microarrays (PAM). Of note, 7 of the 20 
biopsy pairs were obtained from patients who had chronic hepatitis due to 
hepatitis C virus at the time of initiating drug withdrawal [11]. All samples were 
analyzed together to be able to develop classifiers that would identify rejection 
on top of underlying inflammatory lesions. The diagnostic accuracy of the 
resulting rejection-associated signature was evaluated by 4-fold cross-
validation, in which the original sample is randomly partitioned into 4 equal size 
subsamples. Of the 4 subsamples, a single subsample is retained as the 
validation data for testing the model, and the remaining 4-1 sub-samples are 
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used as training data, and the procedure is repeated 40 times. 
 
RESULTS 
 
Patients’ characteristics 
Between January 1988 and December 1999, 654 LTs were performed in 589 
patients at Hospital Clinic Barcelona. At the time of initiating the study 
(December 2007), 312 patients were dead and 38 were lost to follow-up. One 
hundred eighteen patients were excluded due to a previous diagnosis of 
recurrent liver disease or chronic rejection.  Among the 121 evaluable patients, 
67 were finally included in the study and underwent a surveillance liver biopsy 
between December 2007 and December 2009.  The remaining 54 patients were 
excluded for the presence of severe co-morbidities, contraindications for a liver 
biopsy, or refused consent (Figure 1). The characteristics of the patients 
enrolled in the study are shown in Table 1. Briefly, the majority of patients were 
male (n=52, 77.6%), with a median age (at the time of liver biopsy) of 60.4 
years (29.5-75.5). The median time from LT to liver biopsy was 13 years (10-
22). The most common indication for LT was alcoholic cirrhosis (n=23, 34%). 
The most frequent maintenance immunosuppressive regimen at the time of 
biopsy was based on cyclosporine (53.8%; n=36). Independently of the 
immunosuppressive regimen, all patients had low immunosuppressive drug 
levels (below the limit of quantification in 12 [18%] patients) at the time of liver 
biopsy. Following the performance of the surveillance liver biopsy, enrolled 
patients underwent routine follow-up clinical visits every 6 months for a median 
time of 6.8 [range 2-10] years. During the follow-up, 11 patients died (5 died of 
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cardiovascular complications, 3 due to neoplasms, 2 died of end-stage liver 
disease, and 1 patient died of respiratory tract infection) and 4 patients were 
lost to follow-up.   
 
Histological evaluation 
The results of the central histological analysis are shown in Table 2. Histological 
abnormalities were detected in 51 (76%) liver biopsies. Six patients (9%) had 
cirrhosis, 5 (8%) had chronic rejection and 8 (12%) patients had moderate to 
severe hepatic steatosis. The most frequently observed histological abnormality 
was portal inflammation, present in 45 biopsies (67%). Sixteen (35%) out of the 
45 patients exhibited moderate to severe portal inflammation with interface 
hepatitis in 11 patients. Patients with portal inflammation were negative for 
hepatitis B, hepatitis C, and hepatitis E serological markers. While 11 of the 45 
patients with moderate to severe portal inflammation displayed positive 
antinuclear antibodies and/or anti-smooth muscle antibodies in titles ranging 
between 1:40 to 1:640, none of them met criteria of the International 
Autoimmune Hepatitis Group for the diagnosis of autoimmune hepatitis. 
Furthermore, auto-antibodies were also positive in 27 patients with no evidence 
of significant portal inflammation. Of note, 32 (71%) out of the 45 patients with 
portal inflammation had portal or perisinusoidal fibrosis (4 of these patients had 
cirrhosis). On the contrary, among the 22 patients without portal inflammation, 
only 7 (32%) had portal or perisinusoidal fibrosis (p=0.02). By ordinal logistic 
regression analysis, we observed that the severity of inflammation was 
significantly associated with the severity of portal fibrosis. The odds of portal 
fibrosis in patients with moderate or severe inflammation were 6.5 (95%CI 1.48-
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28.17; p=0.013) and 15.2 (95%CI 1.34-172.18; p=0.028), respectively, when 
compared to the absence of inflammation. Centrilobular fibrosis was observed 
in 5 patients, all of whom exhibited moderate to marked portal inflammation 
although concomitant portal fibrosis (F1) was only apparent in 1.  
There were no significant differences among patients with or without portal 
inflammation regarding the type and trough levels of immunosuppressive drugs, 
liver tests, or liver stiffness measurements neither at the time of the protocol 
liver biopsy nor at the last follow-up visit. When specifically analyzing the group 
of patients with portal inflammation, there were not significant differences in the 
baseline characteristics between patients with or without portal/perisinusoidal 
fibrosis. The only variable significantly associated with the presence of fibrosis 
was liver stiffness measurement, which was significantly higher in patients with 
fibrosis than in patients without fibrosis (11.8 vs. 4.8 kPa; p=0.049). 
 
Identification of gene expression modules associated with histological 
abnormalities 
To explore the mechanisms potentially driving the histological abnormalities 
observed in the protocol biopsies, we employed Weighted Gene Correlation 
Network Analysis (WGCNA) to identify modules of genes whose expression is 
coordinated in a similar manner across the whole group of samples. We 
summarized the results in a correlation heatmap, in which the Y-axis 
corresponds to groups of genes (modules) with similar expression, and the X-
axis includes the clinical, serological and histological variables of interest 
(Figure 2). We chose to focus on 2 specific modules, named Cyan and Pink, 
containing 102 and 425 genes respectively, because they showed the most 
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significant positive correlation with portal inflammation, the most prevalent 
histological abnormality, as well as with interface activity and portal fibrosis, 
which are considered markers of progressive histological damage (Figure 2 and 
Supplementary Table 1). The Pink module was most significantly enriched in 
KEGG canonical pathways involved in extracellular matrix remodeling 
(Supplementary Table 2). In contrast, among the genes contained in the Cyan 
module we identified an over-representation of KEGG canonical pathways 
known to be regulated by IFNγ, as well as ATAGC PBT gene sets previously 
reported to be associated with T cell mediated rejection (Supplementary Table 
3). These results suggested a potential link between active portal inflammation, 
fibrosis and T cell mediated rejection. 
 
The gene expression module associated with portal inflammation 
overlaps with the transcriptional signature observed at the time of T cell 
mediated rejection 
To further explore whether the sub-clinical portal inflammatory lesions might 
correspond to unrecognized forms of rejection, we defined a transcriptional 
signature of T cell mediated rejection (TCMR) by re-analyzing the previously 
reported microarray gene expression data derived from 20 liver transplant 
recipients who developed rejection while undergoing protocolized 
immunosuppression withdrawal [11]. Using Predictive Analysis of Microarrays 
(PAM) on the gene expression profiles derived from the 20 pairs of liver 
biopsies (i.e. collected before initiating drug weaning and at the time of 
rejection), we identified a parsimonious group of 13 genes that classified 
samples as either rejecting or non rejecting with high accuracy (Figure 3A and B 
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and Supplementary Table 4 ). We interrogated the RNASeq expression dataset 
from the protocol biopsy set and noted a significant correlation between the 
eigengenes of the group of 13 genes and those of the Cyan and Pink gene 
expression modules (Figure 3C).  
To better understand the biological implications of the changes in the 
expression of these two modules, we decided to concentrate on those samples 
exhibiting extreme transcriptional phenotypes. To do so, we assigned biopsies 
into 2 groups, Cyan&Pink_High and Cyan&Pink_Low, according to whether 
their expression levels were above or below the median level of expression for 
both modules. We then compared the enrichment in rejection-associated gene 
sets between the transcriptome of the Cyan&Pink_High group and the groups of 
post-transplant biopsies with chronic hepatitis C, early TCMR and late TCMR, 
employing the Cyan&Pink_Low group as the common comparator for all 
groups. To conduct this analysis we used the QuSAGE method, which allows 
direct 2-way comparisons between several groups of samples. The 
Cyan&Pink_High group transcriptome was significantly enriched in a number of 
KEGG canonical pathways associated with allograft rejection and 
immunopathology (Table 3). Furthermore, among the ATAGC PBT gene sets, 
the following gene sets known to be associated with T cell mediated rejection 
were also up-regulated in the Cyan&Pink_High group: QCAT (cytotoxic T 
lymphocyte associated transcripts), QCMAT (macrophage transcripts 
associated with rejection), GRIT1 (IFNg dependent rejection-associated 
transcripts), AMAT1 (alternative macrophage associated transcripts correlating 
with T cell mediated rejection), ENDAT (endothelial cell associated transcripts), 
BAT (B cell associated transcripts), IRITD3 and IRITD5 (injury and rejection 
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associated transcripts). A direct comparison between the transcriptional profile 
of the TCMR, late TCMR, and Cyan&Pink_High groups revealed that they were 
very similar at a functional pathway level, with analogous enrichment scores in 
what regards immunopathology pathways and rejection-associated gene sets. 
In contrast, the transcriptomes of these 3 groups differed from the 
transcriptional profile observed in the chronic hepatitis C group, in which, with 
the exception of the GRIT1 and BAT gene sets, no significant enrichment in 
rejection-associated transcript sets was noted (Table 3). The potential for 
progressive liver damage was investigated by quantifying the enrichment in a 
set of 122 genes preferentially expressed by liver stellate cells and known to be 
correlated with the extent of liver fibrosis and with the survival of patients with 
liver cirrhosis [18]. Over-representation of this gene set was only noted on the 
Cyan&Pink_High expression module (Table 3). 
 
Clinical parameters associated with liver tissue gene expression changes 
We next investigated whether the transcriptional differences between the 
Cyan&Pink_High and Cyan&Pink_Low groups were translated into changes in 
clinically-relevant biochemical and hematological parameters, either at baseline 
(at the time of the index protocol biopsy) or at the last follow-up visit. At 
baseline, Cyan&Pink_High patients had significantly higher INR and APRI 
fibrosis score values than the Cyan&Pink_Low patients (p=0.032 and 0.014, 
respectively; Supplementary Table 5). Furthermore, they showed more 
advanced portal inflammation, interface hepatitis and portal fibrosis 
(Supplementary Table 5). At the last follow-up visit, as compared to patients in 
the Cyan&Pink_Low group, patients from the Cyan&Pink_High group continued 
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to have a significantly higher APRI score and in addition they exhibited higher 
FIB-4 fibrosis score, AST and bilirubin, and lower platelet count (Supplementary 
Table 5). To better understand the significance of the changes observed during 
patient follow-up, and to clarify whether Cyan&Pink group assignment exerted 
an effect that was independent from the changes seen at baseline, we re-
analyzed the data employing a non-parametric ANCOVA adjusted by the length 
of the follow-up. This confirmed the significant association between 
Cyan&Pink_High group assignment and the development of higher bilirubin 
level (p=0.0475), lower platelet count (p=0.0025), higher ALT (p=0.0124), and 
higher APRI score (p=0.0277), at the end of the follow-up (Table 4). 
 
DISCUSSION 
 
It is now well established that subclinical chronic allograft injury is very 
prevalent in long-term surviving LT recipients. Previous studies have reported 
histological abnormalities in 5% to 90% of late protocol liver biopsies. In 
children, the prevalence appears to be higher higher ranging between 67% 
and 95% [6,7,21].   The reasons for this variability are not entirely clear but 
they are probably related to differences in the indications for transplantation, 
follow-up duration, immunosuppression protocols, and thresholds for liver test 
levels  [1,19,20]. In most studies, portal inflammation with or without interface 
activity and/or fibrosis, often referred to as idiopathic post-transplant hepatitis, 
was the most frequent finding [6,7,20,19,21–24]. 
The objective of our study was to investigate the mechanisms associated with 
sub-clinical graft deterioration by conducting an unbiased analysis of clinical, 
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histological, biochemical and high-throughput liver tissue transcriptional data. 
In particular, we questioned whether biopsies displaying idiopathic post-
transplant hepatitis corresponded to unrecognized forms of rejection. To 
reduce the risk of bias, provide adequate clinical context and ensure the 
generalizability of the observations, we designed a prospective study in which 
we interrogated all patients transplanted at Hospital Clinic Barcelona over a 
10-year period and we conducted protocol liver biopsies in those meeting pre-
defined inclusion/exclusion criteria.  
We first employed an exploratory systems biology strategy to identify, in an 
unsupervised manner, the key mechanistic underpinnings of the histology 
lesions. This was conducted using a modular analysis that explored the 
correlations between groups of co-expressed genes and semi-quantitative 
histological scores across the whole set of liver tissue samples. Out of the 23 
modules of genes identified, we selected 2 for further analyses, on the basis 
of their significant correlation with portal inflammation and fibrosis. By 
representing each of the 2 expression modules by an ‘eigengene’  we could 
show a significant correlation between the modules and a 13 gene set specific 
for TCMR in LT that we derived from a re-analysis of two previously published 
microarray studies conducted by our group [10,11]. Furthermore, the two 
modules were enriched in gene sets previously identified as being associated 
with allograft rejection across a variety of experimental and clinical settings, 
which again closely resembled what is observed at the time of clinically 
apparent early and late TCMR.  
A non-rejection related form of liver allograft inflammation (recurrent HCV-
induced chronic hepatitis) also exhibited transcriptional similarities with 
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rejection. This reflects the sharing of specific pathways of tissue injury 
between rejection and other inflammatory insults, and is in keeping with what 
has been described in kidney transplantation [25].  However, the degree of 
overlap observed between TCMR and HCV-induced chronic hepatitis was 
significantly smaller than between TCMR and the subset of protocol biopsies 
exhibiting high expression of the two selected modules.  
Although our study lacked paired longitudinal liver biopsies and thus was not 
designed to evaluate the histological progression of allograft damage, the 
analysis of the blood tests collected over time revealed that patients with high 
expression of the two selected gene modules exhibited a mild but significant 
worsening in non-invasive markers of fibrosis, liver function and portal 
hypertension. This was consistent with the over-expression of a distinct set of 
genes known to be specific for stellate cells and whose expression in the liver 
tissue of non-transplant patients with chronic liver disease has been reported 
to be associated with liver failure and patient survival [18]. Taken together, 
these data suggest that idiopathic post-transplant hepatitis is likely to 
constitute a form of unrecognized alloimmune injury that, at least in a subset 
of patients, results in progressive allograft damage. 
Previous studies have reported an association between circulating donor-
specific anti-HLA antibodies (DSA) and subclinical liver allograft inflammatory 
lesions [9,26–29]. The influence of DSA on the liver tissue gene expression 
profile could not be explored in our study due to the lack of donor HLA 
information. The fact that the gene modules correlated with portal 
inflammation and interface activity closely resembled the transcriptome of liver 
TCMR would argue against a significant role for antibody-mediated rejection 
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(ABMR) in this setting. It should be acknowledged, however, that in kidney 
transplantation the transcriptional profile of TCMR and ABMR are known to 
significantly overlap [25], and that transcripts specific for ABMR in liver 
transplantation have not been defined yet. Hence, our study cannot 
unambiguously elucidate the relative roles of cellular and humoral 
alloimmunity. This will require the performance of transcriptional studies of 
large numbers of accurately classified TCMR and ABMR cases.  
The majority of patients enrolled in the current study were on very low dose 
immunosuppression. This reflects the standard practice at Hospital Clinic 
Barcelona and was not the result of an intentional drug minimization protocol. 
Our findings could be interpreted as indicating that long-term surviving liver 
transplant recipients are insufficiently immunosuppressed. This interpretation 
needs to be balanced against the significant morbidity and mortality caused 
by immunosuppressive medications and the fact that evidences of 
progressive allograft damage were only noted in a minority of the patients 
enrolled in our study. Hence, we would caution against the use of more 
aggressive immunosuppressive regimens in this patient population until 
randomized controlled trials investigating the risk/benefit of these regimens 
are conducted. In the meantime, the main practical lesson to be drawn from 
our data is the need to recognize the possibility of subclinical rejection in long-
term surviving liver recipients with normal liver function tests, and to consider 
sequential surveillance liver biopsies as a tool that could potentially optimize 
graft and patient survival.   
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FIGURE LEGENDS 
 
Figure 1: Study participant flow chart. 
 
Figure 2: Identification of gene co-expression modules. Heatmap of the 
23 gene modules (y-axis) identified by weighted gene co-expression network 
analysis of the liver tissue transcriptiome. The clinical and histological 
variables correlated with the gene modules are shown in the x-axis. The 
colour scale in the heatmap corresponds to the magnitude of the Person 
correlation coefficients. Correlations with P value ≤0.01 are denoted by 
asterisks. The CYAN and PINK modules, which showed the most significant 
correlation with the most prevalent histological abnormalities, were selected 
for further analysis.  
 
Figure 3: Transcriptional signature of T cell mediated rejection.  
A) Expression profiles of the 13-gene signature identified by Predictive 
Analysis of Microarrays (PAM) that showed the highest accuracy in classifying 
T cell mediated rejection taking place during immunosuppression withdrawal. 
The analysis was performed by comparing the expression profile of liver 
biopsies collected before initiation of drug weaning (baseline) with liver 
biopsies collected at the time of rejection. Results are expressed as a matrix 
view of gene expression data where rows represent genes and columns 
represent hybridized samples. The intensity of each colour denotes the 
standardized ratio between each value and the average expression of each 
gene across all samples. Red coloured pixels correspond to an increased 
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abundance of the mRNA in the indicated blood sample, whereas green pixels 
indicate decreased mRNA levels. B) Receiver operating characteristic (ROC) 
curves displaying the overall diagnostic performance of the 13-gene 
transcriptional signature in classifying liver biopsies as rejecting or non-
rejecting. The dotted line curve corresponds to the 4-fold cross-validated data.  
C) Correlation of the CYAN and PINK gene modules with the 13-gene 
classifier of T cell mediated rejection. To reduce the multi-dimensionality, 
consensus eigengenes from each of the 3 sets of genes were first generated. 
Correlation was analyzed using Person’s coefficient.  
 
  
 
 
 
  
  
 
  
Figure 2: Weighted gene co-expression network analysis of liver tissue transcriptome 
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Table 1. Characteristics of the patients included in the study (n=67) 
Characteristic  
Age (years) 60.4 (29.5-75.5) 
Male gender (n,%) 52 (77.6%) 
Indication for LT (n,%) 
      Alcoholic cirrhosis 
      Hepatitis B-related cirrhosis 
      Cryptogenic 
      Fulminant hepatitis B 
      Unknown etiology fulminant hepatitis 
      Other 
 
23 (34.3%) 
15 (22.4%) 
9 (13.4%) 
5 (7.5%) 
5 (7.5%) 
10 (14.9%) 
Time from LT to liver biopsy (years) 13 (10-22) 
Comorbidities (n,%) 
      Diabetes Mellitus 
      Arterial hypertension 
      Dylipemia 
      Cardiovascular disease 
 
9 (13.4%) 
25 (37.3%) 
14 (20.9%) 
3 (4.5%) 
Immunosuppression (n,%) 
      Cyclosporine (± MMF) 
      Tacrolimus (± MMF) 
      mTOR inhibitor (monotherapy) 
      MMF (monotherapy) 
 
36 (53.8%) 
11 (16.4%) 
3 (4.5%) 
17 (25.3%) 
     Cyclosporine trough levels (ng/mL) 32 (0-143) 
     Tacrolimus trough levels (ng/mL) 1.6 (0-7.4) 
     Sirolimus trough levels (ng/mL) 3.6 
     Everolimus trough levels (ng/mL) 3.3 (2.5-4.1) 
AST/ALT (IU/mL) 26 (11-53)/25 (3-74) 
AP/GGT (IU/mL) 173 (24-494)/40 (3-434) 
Biochemistry 
   Bilirubin (mg/dL) 
 
0.7 (0.3-2.9) 
   Prothrombin time (%) 94 (59-100) 
   Albumin  (g/dL) 42 (35-68) 
   White blood cell count (x 103/mm3) 6.15 (2-9.6) 
   Platelet count (x 103/ mm3) 182 (64-355) 
Transient elastography (Fibroscan) 4.95 (3.4-33.8) 
APRI score 0.34 (0.12-1.48) 
FIB4 score 1.61 (0.62-9.20) 
Continuous data are expressed as median (range).  
Abbreviations: LT (liver transplantation), MMF (mofetil mycophenolate), mTOR (mammalian target of 
rapamycin).  
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Table 2. Histological characteristics of baseline protocol liver biopsies 
 
 
Histological Evaluation 
 
Median 
(range) 
0 
 
1 2 3 4 
Number of complete portal tracts  
 
8 (1-18)      
Number of central veins 
 
6 (0-13)      
Architectural abnormalities 0 (0-2) No 
45 (67%) 
Mild 
12 (18%) 
Moderate-marked 
10 (15%) 
  
Lobular inflammation  
 
0 (0-2) No 
35 (52%) 
Mild 
27 (40%) 
Moderate 
5 (8%) 
Marked 
0 
 
Central perivenulitis    
 
0 (0-2) No 
56 (84%) 
Mild 
8 (12%) 
Moderate 
3 (4%) 
Marked 
0 
 
Portal inflammation    
 
1 (0-3) No 
22 (33%) 
Mild 
29 (43%) 
Moderate 
14 (21%) 
Marked 
2 (3%) 
 
Interface hepatitis    
 
0 (0-2) No 
49 (73%) 
Mild 
12 (18%) 
Moderate 
6 (9%) 
Marked 
0 
 
Bile duct lesions    
 
0 (0-1) No 
51 (76%) 
Mild 
16 (24%) 
Moderate 
0 
Marked 
0 
 
Bile duct loss    
 
0 (0-2) No 
62 (92%) 
<50% 
4 (6%) 
>50% 
1 (2%) 
  
Portal vein branches    
 
0 (0-2) Present in all 
42 (63%) 
Absence in a minority 
11 (16%) 
Absence in a majority 
2 (3%) 
  
Portal vein endothelitis    
 
0 (0-1) No 
49 (73%) 
Mild 
18 (27%) 
Moderate 
0 
Marked 
0 
 
Portal fibrosis  (METAVIR score) 
 
0 (0-4) No 
38 (57%) 
Minimal 
13 (19%) 
Moderate 
9 (13%) 
Bridging 
1 (2%) 
Cirrhosis 
6 (9%) 
Perisinusoidal fibrosis 
 
0 (0-2) No 
40 (60%) 
Focal 
20 (30%) 
Marked 
7 (10%) 
  
Esteatosis 0 (0-3) No 
38 (57%) 
Mild 
20 (30%) 
Moderate 
6 (9%) 
Severe 
2 (3%) 
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Highlights 
- Histological abnormalities are frequently observed in long-term liver 
transplant recipients despite the presence of normal or near normal liver 
tests, 
- Recipients with portal inflammation with/without fibrosis exhibit a liver 
tissue transcriptional profile closely resembling what is observed in the 
setting of T-cell mediated rejection. 
- Recipients exhibiting subclinical lesions and high expression of rejection-
associated transcripts are at risk of developing progressive liver damage.  
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Table 3. Enrichment of rejection and stellate cell associated gene sets in study groups employing Quantitative Set Analysis 
for Gene Expression (QuSAGE). 
Gene Set Description Cyan&Pink 
 High (FDR) 
 T-cell mediated    
      rejection 
           (FDR) 
     Late 
  Rejection 
      (FDR)  
Hepatitis C      
  infection 
     (FDR) 
QCAT* Transcripts associated with cytotoxic T lymphocytes defined in purified cell lines; associated 
with TCMR in renal transplants with expression levels correlating with T cell infiltration. 
0.0006 0.1300 0.0143 0.7020 
QCMAT* Macrophage associated transcripts defined in purified cell lines, associated with TCMR in 
kidney patients. 
0.0027 3e-06 0.0241 0.1060 
GRIT1* Human orthologs of IFN-γ dependent, rejection-associated transcripts defined in mice; 
expressed in TCMR, especially in association with AMAT1. 
0.0025 3e-06 0.0143 0.0027 
DSAST* DSA-positive-specific transcripts derived from comparative analysis of DSA with or without 
renal biopsies; observed both in ABMR and TCMR with higher levels in ABMR. 
0.4540 0.0010 0.4090 0.5470 
AMAT1* Alternative Macrophage Associated Transcript 1; human orthologs of mouse data; high GRIT1 
plus AMAT1 scores correlate with TCMR correlate with TCMR. 
0.0400 0.0203 0.0721 0.1450 
IGT* Immunoglobulin associated transcripts, observed both in ABMR and TCMR and associated 
with allograft fibrosis. 
0.2510 0.8270 0.7760 0.3120 
ENDAT* Endothelial cell associated transcripts derived from purified cell lines; increased in ABMR  
and TCMR with higher levels in ABMR. 
0.0040 0.9070 0.2610 0.1450 
IRRAT* Injury-repair response associated with transcripts, defined in early renal transplants with no 
rejection, derived as a model for acute kidney injury. 
0.2570 0.0064 0.2610 0.0917 
NKB* Natural killer cell-specific transcripts derived from purified cells lines; identified in early  
TCMR and late ABMR in renal patients. 
0.9090 0.0387 0.9720 0.1450 
TCB* T cell-specific transcripts based on purified cell lines. 0.0448 0.2930 0.5080 0.9430 
BAT* B cell-associated transcripts derived from purified B cells; upregulated in both ABMR and 
TCMR. 
0.0005 0.6090 0.0143 0.0354 
MCAT* Mast cell associated transcripts, associated with scarring and poor survival in renal 
transplants. 
0.0875 0.0266 0.9250 0.6300 
IRITD3* Injury and rejection induced transcripts upregulated 3 days after isograft transplant 
(humanized results from mouse model). 
0.0025 0.0013 0.0421 0.1450 
IRITD5* Same as for IRITD3 but measured on day 5. 0.0008 0.0203 0.0355 0.1060 
Stellate Cell 122-gene set preferentially expressed in hepatic stellate cells and that correlates with the 
extent of liver fibrosis and is associated with patients survival in cirrhosis. 
0.0880 0.1890 0.7760 0.6400 
* Pathogenesis-Based Transcript gene sets from the Alberta Transplant Applied Genomics Centre. 
Abbreviations: TCMR (T cell mediated rejection), ABMR (antibody mediated rejection), DSA (donor specific antibodies), FDR (False Discovery Rate). 
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Table 4.  Characteristics of patients grouped according to their baseline liver tissue module gene expression profile 
Variable Cyan&Pink_High  
(n=12) 
Cyan&Pink_Low 
(n=13) 
 
p value 
(change in High vs Low 
groups) 
Baseline Last 
Follow-up 
Baseline Last 
Follow-up 
Bilirubin (mg/dL) 0.8 (0.6-2.7) 1 (0.4-45) 0.6 (0.3-1.9) 0.6 (0.2-1.7)  
mean change# 0.15 (-0.06 , 0.41) -0.10   (-0.22 , 0.09) 0.0475 
AST (IU/mL) 29 (17-44) 30 (25-60) 22 (13-53) 21 (13-41)  
     mean change# 3.90 ( -0.17 , 8.39) -0.44 (-4.92 , 4.43) 0.1005 
ALT (IU/mL) 25 (16-45) 26 (18-76) 17 (3-61) 18 (8-61)  
     mean change# 2.47 (-1.923 ,8.81) -4.90   (-9.00 , 0.55) 0.0124 
GGT (IU/mL) 24 (13-345) 29 (15-662) 51 (10-118) 47 (3-303)  
     mean change# 28.05 (-1.85 , 80.35) 4.70 (-13.04 , 36.30) 0.2360 
INR 1.1 (1-1.3) 1.0 (1-2.4) 1.0 (1-1.1) 1.0 (0.8-3.6)  
    mean change# 0.02 (-0.03, 0.08) 0.04 (-0.01, 0.10) 0.2371 
Platelet count (x109) 155 (76-262) 145 (15-662) 219 (116-333) 262 (97-370)  
   mean change# -19 (-51 , 12) 
 
51 (7,   100) 0.0025 
APRI 0.44 (0.2-1.45) 0.51 (0.3-4.6) 0.268 (0.12-0.96) 0.25 (0.09-0.89)  
   mean change# 0.11 (0.02, 0.25) 
 
0.01 (-0.07, 0.09) 0.0277 
FIB4 1.8 (0.9-7.1) 2.47 (1.2-23) 1.61 (0.6-2.4) 1.24 (1-3.48)  
   mean change# 1.23 (0.26,  3.24) 
 
0.35 (-0.16, 1.34) 0.1109 
Baseline and follow-up data are expressed as median (range).Variables were compared by a non-parametric ANCOVA. P-values correspond to the 
comparisons of the changes observed in the two groups, adjusted by the baseline values and the time of follow-up. # Estimated mean change (with 95% CI), 
adjusted for mean baseline values and mean length of follow-up 
